Inhibrx Biosciences Inc

Research Inhibrx Biosciences Inc (INBX) on Bullrun: market cap USD 1.40B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerINBX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.40B
• Financial periodFY2025
• RevenueUSD 1.30M
• Revenue growth550.0%
• Net income-USD 140.06M
• Free cash flow-USD 129.83M

Valuation Snapshot

latest market cap is USD 1.40B.

About Inhibrx Biosciences Inc

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma;

Frequently asked questions

What is Inhibrx Biosciences Inc's market cap?

Inhibrx Biosciences Inc's market capitalization is USD 1.40B.

What does Inhibrx Biosciences Inc do?

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.